These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Kennedy AS; Dezarn WA; McNeillie P; Coldwell D; Nutting C; Carter D; Murthy R; Rose S; Warner RR; Liu D; Palmedo H; Overton C; Jones B; Salem R Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307 [TBL] [Abstract][Full Text] [Related]
6. Radioembolization in patients with hepatic metastases from breast cancer. Jakobs TF; Hoffmann RT; Fischer T; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Reiser MF; Helmberger TK J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456 [TBL] [Abstract][Full Text] [Related]
7. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526 [TBL] [Abstract][Full Text] [Related]
8. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Cao CQ; Yan TD; Bester L; Liauw W; Morris DL Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229 [TBL] [Abstract][Full Text] [Related]
9. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231 [TBL] [Abstract][Full Text] [Related]
10. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059 [TBL] [Abstract][Full Text] [Related]
11. Radioembolization with infusion of yttrium-90 microspheres into a right inferior phrenic artery with hepatic tumor supply is feasible and safe. Burgmans MC; Kao YH; Irani FG; Dames EL; Teo TK; Goh AS; Chow PK; Tay KH; Lo RH J Vasc Interv Radiol; 2012 Oct; 23(10):1294-301. PubMed ID: 22922039 [TBL] [Abstract][Full Text] [Related]
12. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020 [TBL] [Abstract][Full Text] [Related]
13. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V Oncology; 2014; 86(1):24-32. PubMed ID: 24401529 [TBL] [Abstract][Full Text] [Related]
14. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. Bester L; Meteling B; Pocock N; Pavlakis N; Chua TC; Saxena A; Morris DL J Vasc Interv Radiol; 2012 Jan; 23(1):96-105. PubMed ID: 22079516 [TBL] [Abstract][Full Text] [Related]
15. Optimization of radioembolic effect with extended-shelf-life yttrium-90 microspheres: results from a pilot study. Lewandowski RJ; Riaz A; Ryu RK; Mulcahy MF; Sato KT; Kulik LM; Gates VL; Baker T; Omary R; Salem R J Vasc Interv Radiol; 2009 Dec; 20(12):1557-63. PubMed ID: 19854068 [TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Saxena A; Bester L; Chua TC; Chu FC; Morris DL Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691 [TBL] [Abstract][Full Text] [Related]
17. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019 [TBL] [Abstract][Full Text] [Related]